Improving cancer treatment by targeting specific MET mutations
Maximizing Selective Inhibition of Clinically Observed MET Mutants
This study is looking at new ways to improve cancer treatment by targeting specific changes in the MET gene that can make tumors grow, especially in lung cancer and melanomas, to help find the best medicines for patients based on their unique cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-11070196 on NIH RePORTER |
What this research studies
This research focuses on enhancing cancer therapy by selectively inhibiting mutations in the MET gene, which is known to drive tumor growth in various cancers, including non-small cell lung cancer and melanomas. The approach involves using multiple inhibitors that target the same therapeutic pathway to prevent cancer cells from developing resistance to treatment. By identifying which inhibitors work best for specific MET mutations, the research aims to optimize treatment strategies for patients. This could lead to more effective and personalized cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit MET mutations, particularly those with non-small cell lung cancer or melanoma.
Not a fit: Patients without MET mutations or those with cancers not driven by MET may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that reduce the chances of resistance and improve patient outcomes.
How similar studies have performed: Other research has shown promise in using combination therapies to overcome resistance in cancer treatment, indicating that this approach may be effective.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Outhwaite, Ian — State University New York Stony Brook
- Study coordinator: Outhwaite, Ian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.